Abstract 277P
Background
To characterize ductal adenocarcinoma of the prostate by comparing VASH1 expression levels in ductal and acinar adenocarcinoma of the prostate.
Methods
125 patients who underwent radical prostatectomy or transrectal resection over the past 5 years, 14 patients diagnosed with ductal adenocarcinoma and 20 patients with acinar adenocarcinoma with Gleason scores of 4+4 were included in the study. VASH1 density was taken as the number of activated endothelial cells (number of vessels per mm2), microvessel density (MVD) was determined through CD34 expression, all results were obtained by immunohistochemistry. The main method for evaluating the results was to determine the presence of a relationship between MVD and VASH1 density in ductal and acinar adenocarcinoma, the secondary method for evaluating the results was the oncological outcomes of these forms of cancer.
Results
9 patients (64.3%) with ductal adenocarcinoma were diagnosed with advanced clinical stage and 5 patients (35.7%) died of cancer during a median follow-up period of 56.0 months. VASH1 density (mean ± SD) in ductal and acinar adenocarcinoma was 45.1 ± 18.5 vs. 16.1 ± 21.0 (p < 0.001), respectively, while MVD (mean ± SD) in ductal and acinar adenocarcinoma was 65.3 ± 21.9 versus 80.8 ± 60.7. (p = 0.666), respectively. The five-year survival rate for high and low VASH1 expression was 70.0% and 100.0% (p = 0.006), respectively. High expression of VASH1 and diagnosis of ductal adenocarcinoma were important predictors of survival.
Conclusions
Ductal adenocarcinoma has more aggressive growth and higher expression of VASH1 than acinar adenocarcinoma, with MVD rates being equivalent in both forms of prostate cancer. The obtained results suggest that the level of VASH1 expression may be a new biomarker for the aggressive course of ductal adenocarcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Republican Cancer Research Center of Uzbekistan.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract